Ellen Berg, PhD

Ellen L. Berg, PhD is an entrepreneur and scientific leader in drug discovery technology innovation.  She is Chief Scientific Officer, Translational Biology for Eurofins Pharma Discovery Services and a principle at Alto Predict LLC. Dr. Berg was the lead inventor of the BioMAP^® platform of human primary cell-based disease models, now successfully commercialized by Eurofins and serving the pharmaceutical and consumer products industries to deliver safer and more effective products. In previous positions, Dr. Berg was co-founder and CSO of BioSeek, Inc. and led a research team at Protein Design Labs, Inc. She received her PhD from Northwestern University and was a postdoctoral fellow at Stanford University, where she was a fellow of the American Cancer Society and a Special Fellow of the Leukemia Society of America. Dr. Berg has served in various positions with the Society of Laboratory Automation and Screening (SLAS), is a board member of the American Society for Cellular and Computational Toxicology (ASCCT), and a member of the Society of Toxicology (SOT) and Inflammation Research Association. Her research interests include human-based in vitro systems, drug and toxicity mechanisms of action, phenotypic drug discovery, and predictive methods for human efficacy and safety outcomes. She is currently focused on working with industry, academic and government stakeholders to incorporate non-animal, human-based in vitro and in silico predictive models into regulatory guidances. Dr. Berg holds several patents in the field of inflammation, and has authored over 80 publications.